Precision Medicine and Genomics Market
Quality and regulatory compliance heads
One size does not fit all, especially in cancer treatment. Precision medicine uses genetic information about a patient’s tumour or inherited DNA to guide treatment decisions. By identifying specific biomarkers, oncologists can prescribe targeted therapies that are far more effective and less toxic than traditional chemotherapy. This approach is underpinned by Next Generation Sequencing (NGS) technology, which has seen its costs plummet over the last decade. The market extends beyond oncology into rare genetic disease diagnosis, non invasive prenatal testing (NIPT), and pharmacogenomics (predicting drug response).
What Numbro covers:
Global market sizing for NGS instruments, consumables, and bioinformatics software for clinical applications. Companion diagnostic co development models between pharmaceutical companies and diagnostic firms. Reimbursement landscape analysis for comprehensive genomic profiling panels from payers in the US, Europe, and emerging markets. India specific market analysis of direct to consumer genetic testing and the growth of oncology focused molecular pathology labs.
- Oncologists and pathologists
- Pharmaceutical R&D teams in targeted oncology
- Diagnostic laboratory chains
- Health insurance actuarial teams
